Home > Oncology > Illumina launches multiple-gene test to spot rare treatable cancers

Illumina launches multiple-gene test to spot rare treatable cancers


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Reuters - 15/03/2022 - Genome sequencing group Illumina on Tuesday launched a cancer test in Europe that checks for a wide range of tumour genes in one tissue sample, potentially helping patients with rare diseases to be matched up with treatment options. The test, which Illumina says scans for more mutations than any available kits, comes amid drug industry efforts to develop precision oncology drugs for ever smaller patient groups defined by a genetic profile. This has created pent-up demand for more sophisticated diagnostic tools. Illumina's TruSight Oncology Comprehensive test kit scans for 517 cancer-relevant genes across nearly 30 solid tumour types, it said in a statement. For instance, it reads out a patient's mutational burden score and microsatellite instability status, which cancer researchers have said indicate the need to be given immune drugs such as Merck & Co's Keytruda. Also included is the TRK mutation, which is a genetic driver i...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on